Global In Vitro Fertilization (IVF) Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 - 2023

  • ID: 3050452
  • Report
  • Region: Global
  • 135 pages
  • Occams Business Research and Consulting
1 of 5

FEATURED COMPANIES

  • Andrology Solutions
  • Auxilium Pharmaceuticals
  • Auxogyn
  • Ferring Pharmaceuticals
  • Genea
  • Halotech DNA
  • MORE
Infertility is one of the major concerns in the world. One out of six couples in the world suffers from some form of infertility. About 10% women aged 20-44 suffer from infertility. There are various causes for infertility which include physiological (20-30% cases), some cases include genetically induced disorders whereas sometimes it may be self induced as in case of contraceptive surgeries. The market is driven by rising awareness amongst couples, a strong and developed health structure in developing nations, low cost treatment options available, and rise in the new methods like in vitro activation and surrogacy.

The testing and treatment market is growing at a faster rate in males than females. The earlier social taboos among men regarding male fertility have been declining, leading to increase in the male infertility testing and treatment market.

The cost of fertility treatment varies vastly from country to country leading to a rise in medial tourism in relationship with fertility treatments Israel is one of the leading countries with high quality treatments for infertility. The success rate of infertility treatment in Israel is around 46% which in one of the best globally
.

The companies profile in this report include
:

1. Merck Sereno
2. Origio
3. Vitrolife AB
4. Axilium Pharma
5. Andology Solutions
6. Auxillum Pharmaceuticals
7. Auxogyn
8. Ferring Pharmaceuticals
9. Genea
10. Helotech DNA
11. Ovascience

This Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2022
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies

Note:
Please allow up to 72 hours for delivery.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Andrology Solutions
  • Auxilium Pharmaceuticals
  • Auxogyn
  • Ferring Pharmaceuticals
  • Genea
  • Halotech DNA
  • MORE
Chap 1. Executive Summary
Chap 2. Market overview
2.1. Market Share for Drug & Hormone Therapy
2.2. Key buying criteria
2.2.1. Treatment options
2.2.2. Quality of medical procedures
2.2.3. Price of treatments
2.2.4. Shift towards medical tourism
2.2.5. Reimbursement
2.3. Key Findings
2.3.1. highest growth in Male infertility treatment segment
2.3.2. Fertility tourism- The biggest and the growing trend
2.3.3. Upper middle income group is the key target
2.3.4. Regulatory environment key market enabler
2.3.5. Surrogacy preferred for failures in IVF treatments
2.3.6. Technological advancement enhancing success rates of fertility treatments
Chap 3. Male and Female Infertility
3.1. Causes
3.1.1. Causes of male infertility
3.1.1.1. Medical reasons
3.1.1.2. Environmental factors
3.1.1.3. Lifestyle issues
3.1.2. Causes of female infertility
3.1.2.1. Ovulatory disorders
3.1.2.2. Poor functioning or damage to fallopian tube and other issues
3.2. Ethical issues in infertility treatment
Chap 4. Market Determinants
4.1. Market Drivers
4.1.1. Rise in infertility
4.1.2. Fertility Tourism
4.1.3. Surrogacy also responsible for fertility tourism
4.1.4. Technological advancement in healthcare domain
4.1.5. Increase in success rate of treatments
4.1.6. Increasing acceptance of donor eggs by consumers
4.2. Market Restraints
4.2.1. Expensive procedure
4.2.2. Legal issues
4.3. Market Opportunities
4.3.1. Global requirement for low cost instruments and drugs in IVF
4.3.2. IVF an attractive sector for investment for private equity investors
4.3.3. Reproductive tourism
4.4. Market Challenges
4.4.1. Cost barrier for locals in emerging economies
4.4.2. Low acceptance of infertility treatment amongst men
4.4.3. Multiple births and birth defects
Chap 5. Market Segmentation
5.1. Male Infertility Market
5.1.1. Male Infertility tests
5.1.1.1. Semen analysis techniques
5.1.1.1.1. CASA provides more accurate results in lesser time
5.1.1.2. DNA fragmentation
5.1.1.2.1. Importance of sperm DNA fragmentation
5.1.1.2.2. When the test is conducted
5.1.1.2.3. Causes of Sperm DNA fragmentation
5.1.1.3. Oxidative Stress Analysis
5.1.1.4. Testicular Biopsy
5.1.1.5. Azoospermia is the reason in 15 percent infertile males
5.1.1.6. Risks in testicular biopsy
5.1.1.7. CNB and FNA Mapping is an emerging trend
5.1.2. Male infertility treatment types
5.1.2.1. Surgery
5.1.2.1.1. Vasovasectomy and Vasoepididymostomy (Vasectomy reversal)
5.1.2.1.2. Sperm Retrieval Treatment
5.1.2.1.2.1. Microsurgical Sperm Aspiration (MESA)
5.1.2.1.2.2. Testicular Sperm Extraction (TESE)
5.1.2.1.3. Varicocele repairs
5.1.2.1.4. Drug & Hormone Therapy
5.1.2.1.5. Assisted Reproductive Techniques (ART)
5.1.2.1.5.1. Intrauterine insemination (IUI)
5.1.2.1.5.2. In vitro fertilization (IVF)
5.1.2.1.5.3. Intra cytoplasmic sperm injection (ICSI)
5.2. Female infertility
5.2.1. Female infertility test
5.2.1.1. Ovulation Testing
5.2.1.2. Hysterosalpingography
5.2.1.3. Laparoscopy
5.2.1.4. Ovarian reserve testing
5.2.1.5. Genetic Testing
5.2.2. Female infertility treatment types
5.2.2.1. In vitro fertilization
5.2.2.2. Intrauterine insemination (IUI)
5.2.2.3. Drug and hormone therapies
Chap 6. IVF & Infertility market geography wise
6.1. North America
6.1.1. US
6.1.2. Canada
6.1.2.1. Regulation for IVF in Canada
6.2. Asia
6.2.1. China
6.2.2. India
6.2.2.1. Growing fertility tourism in India
6.2.2.2. Need for a regulatory framework
6.2.3. Japan
6.2.3.1. Fertility Regulations in Japan
6.2.4. South Korea
6.2.5. Thailand
6.3. Europe
6.3.1. Italy
6.3.2. France
6.3.2.1. Regulations in France
6.3.2.2. Low cost treatment with social security cover in France
6.3.3. Germany
6.3.3.1. Coverage Policy
6.3.3.2. Regulations
6.3.4. Spain
6.3.4.1. Regulations in Spain
6.3.5. Russia
6.3.5.1. Regulations
Chap 7. Company Profiling
7.1. Andrology Solutions
7.1.1. Overview
7.1.2. Product Portfolio
7.1.3. SCOT Analysis
7.2. Auxilium Pharmaceuticals
7.2.1. Overview
7.2.2. Product Portfolio
7.2.3. Revenue Analysis
7.2.4. Strategic Moves
7.2.5. SCOT Analysis
7.3. Auxogyn
7.3.1. Overview
7.3.2. Products
7.3.3. Strategic Moves
7.3.4. SCOT Analysis
7.4. Ferring Pharmaceuticals
7.4.1. Overview
7.4.2. Product Portfolio
7.4.3. Strategic Moves
7.4.4. SCOT Analysis
7.5. Genea
7.5.1. Overview
7.5.2. Product Portfolio
7.5.3. Strategic Moves
7.5.4. SCOT Analysis
7.6. Halotech DNA
7.6.1. Overview
7.6.2. Product Portfolio
7.6.3. Strategic Moves
7.6.4. SCOT Analysis
7.7. Irvine Scientific
7.7.1. Overview
7.7.2. Product Portfolio
7.7.3. Strategic Moves
7.7.4. SCOT Analysis
7.8. Merck Serono
7.8.1. Overview
7.8.2. Product Portfolio
7.8.3. Revenue Analysis
7.8.4. Strategic Moves
7.8.5. SCOT Analysis
7.9. Origio
7.9.1. Overview
7.9.2. Product Portfolio
7.9.3. Strategic Moves
7.9.4. SCOT Analysis
7.10. Ovascience
7.10.1. Overview
7.10.2. Product Portfolio
7.10.3. Strategic Moves
7.10.4. SCOT Analysis
7.11. Vitrolife AB
7.11.1. Overview
7.11.2. Strategic Moves
7.11.3. SCOT Analysis
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Andrology Solutions
Auxilium Pharmaceuticals
Auxogyn
Ferring Pharmaceuticals
Genea
Halotech DNA
Irvine Scientific
Merck Serono
Origio
Ovascience
Vitrolife AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll